JAIDS Journal of Acquired Immune Deficiency Syndromes:
Letter to the Editor
Implications of the Henan Province Report on the Treatment as Prevention Debate
Montaner, Julio MD*; Hogg, Robert†
*Department of Medicine, University of British Columbia, Vancouver, BC; †Faculty of Health Sciences, Simon Fraser University, Burnaby, BC
The authors have no funding or conflicts of interest to disclose.
To the Editors:
Wang et al1 provide retrospective data regarding highly active antiretroviral therapy coverage, HIV incidence, and behavioral, clinical, and quality-of-life risk factors for HIV transmission among serodiscordant couples from Henan Province, China.1 The study found that HIV seroconversion rates were generally low over time. HIV seroconversion was associated with not always using condoms, having sexual activity 4 or more times per month, not switching antiretroviral treatment regimens, and having a high quality-of-life score on the psychological domain. Use of antiretroviral therapy by the seropositive member of the couple was not found to be protective against HIV seroconversion.
Although these findings are reaffirming of how psychological and sexual behaviours are implicated in seroconversion, they do not add meaningfully to the discussion regarding the role of antiretroviral treatment as prevention. We are surprised that this is not highlighted in the accompanying editorial.2 Quite simply, and as acknowledged by Wang et al,1 HIV transmission is directly associated with the level of virus present in the HIV-positive partner,3 and they are unable to assess this relationship in this analysis, as they do not have data on longitudinal plasma HIV-1 virel load. As they note in the discussion, they do not even have data on adherence levels among those on therapy. Furthermore, the relationship described in this study between seroconversion and not switching antiretroviral treatment suggests that virological failure may indeed be playing an important role as a driver of HIV transmission. Complete monitoring of relevant variables, most critically plasma viral load, is essential to address the relationship between antiretroviral therapy coverage and HIV transmission.4-8
Julio Montaner, MD*
Robert Hogg, PhD†
*Department of Medicine, University of British Columbia, Vancouver, BC
†Faculty of Health Sciences, Simon Fraser University, Burnaby, BC
1. Wang L, Ge Z, Luo S, et al. HIV transmission risk among serodiscordant couples: a retrospective study of former plasma. J Acquir Immune Defic Syndr
2. Cohen M. HIV treatment as prevention: to be or not to be? J Acquir Immune Defic Syndr
3. Quinn TC, Wawer MJ, Sewankambo N, et al, For the Rakai Project Study Group. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med
4. S Attia, M Egger, M Muller, et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS
5. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission of antiretroviral therapy: a prospective cohort analysis. Lancet
6. Wood E, Kerr T, Marshall B, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ
7. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet
8. Das, M, Cu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One
© 2011 Lippincott Williams & Wilkins, Inc.